Dermal Cell News 6.12 April 6, 2020 | |
| |
TOP STORYThe authors showed that MEK and RAF inhibitors did not suppress levels of SOX10 protein in patient-derived cells in vitro, as well as in melanoma patients in vivo. [Oncogene] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DERMAL STEM CELLS & TISSUE REGENERATIONScientists demonstrated that PABPN1 deficiency inhibited cell growth, which could be rescued by ectopic ΔNp63α. They showed that PABPN1 controlled the terminal differentiation of HaCaT keratinocytes by modulating ΔNp63α expression. [J Invest Dermatol] Abstract Albendazole Negatively Regulates Keratinocyte Proliferation The authors investigated whether albendazole, an anti-helmintic drug that regulates epithelial cell function in various systems, inhibits keratinocyte proliferation in models of psoriasis. [Clin Sci (Lond)] Full Article Scientists compared the responses to melanocyte‐keratinocyte transplantation procedure in segmental vitiligo with and without adding growth factors to the suspension medium. [Dermatol Ther] Abstract Macrophage-Derived Extracellular Vesicle Promotes Hair Growth Investigators analyzed the role of macrophage-derived Wnts and macrophage extracellular vesicles (MAC-EVs) in promoting hair growth. They studied the proliferation, migration, and expression of growth factors of human-dermal papilla cells in the presence or absence of MAC-EVs. [Cells] Full Article SKIN CANCERS & DISORDERSScientists evaluated the effect of CAV1 and c-Abl overexpression, as well as the use of the Src-family kinase inhibitors, PP2 and dasatinib in lung metastasis of B16F10 melanoma cells. [Biochem Pharmacol] Abstract | Graphical Abstract Researchers demonstrated the effectiveness of melanoma vaccines composed of genetically modified tumor cells admixed with melanoma stem-like cells or induced pluripotent stem cells. [Vaccines] Full Article The effects of long-term treatment with PLX4032 were studied in vitro on sensitive V600E BRAF-mutated melanoma cell lines. After several weeks of treatment with PLX4032, the majority of the melanoma cells died; however, a proportion of cells remained viable and quiescent, presenting senescent cancer stem cell-like characteristics. [Int J Oncol] Abstract | Download Full Article Scientists generated a library consisting of 420 sgRNAs, performed sgRNA tracking analysis, and assessed the effect size of the response to vemurafenib in a human melanoma cell line, which has been well-studied via knockout-based drop-out screens. [Commun Biol] Full Article Subscribe to one of our other 19 science newsletters such as Extracellular Matrix News & Cancer Stem Cell News. | |
| |
REVIEWSNew Insights into the Functions of Cox-2 in Skin and Esophageal Malignancies The authors review experimental evidence aiming to define the origins of skin and esophageal cancers and discuss how Cox-2 contributes to tumorigenesis and differentiation. [Exp Mol Med] Full Article Visit our reviews page to see a complete list of reviews in the dermal cell research field. | |
| |
INDUSTRY NEWSDermavant Sciences announced the completion of patient enrollment in the company’s PSOARING 1 and PSOARING 2 clinical trials of tapinarof, a potential first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent, in adult patients diagnosed with plaque psoriasis. [Dermavant Sciences] Press Release Menlo Therapeutics Inc. announced top line results from two Phase III clinical trials evaluating the safety and efficacy of once daily oral serlopitant for the treatment of pruritus associated with prurigo nodularis, studies MTI-105 and MTI-106. [Menlo Therapeutics Inc.] Press Release Mallinckrodt plc announced that Stratatech has initiated the rolling submission of a Biologics License Application to the FDA seeking approval to market StrataGraft®, a regenerative skin tissue therapy, for the treatment of adult patients with deep partial-thickness thermal burns. [Mallinckrodt plc] Press Release Soligenix, Inc. announced that the European patent office has granted the divisional patent application titled “Formulations and Methods of Treatment of Skin Conditions”. [Soligenix, Inc.] Press Release | |
| |
POLICY NEWSSafely Conducting Essential Research in the Face of COVID-19 Some scientists can’t simply stop going to their laboratories — especially not those who are overseeing clinical trials that could offer life-saving vaccines and therapies, particularly against the new coronavirus. And some research activities must continue even in the face of a shutdown. [Nature News] Editorial NIH’s Process for Removing Reviewers Remains a Mystery, Watchdog Finds A new report by the Office of Inspector General of National Institute of Health’s (NIH’s) parent body, the Department of Health and Human Services, documents how NIH has begun to remove reviews who breached NIH standards on research integrity. [ScienceInsider] Editorial
| |
EVENTSIn light of COVID-19, many conferences are being cancelled or postponed. As such: We are suspending new event postings in our newsletters and on Twitter. Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Professor – Molecular Physiology (Karolinska Institutet) Postdoctoral Research Associate or Research Associate – DNA Damage (Washington State University) PhD Student Position – Skin and Single-Cell Biology (Karolinska Institutet) Postdoctoral Scholar – Cancer Research (The Ohio State University) Assistant Professor – Dermatology (Massachusetts General Hospital) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Dermal Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|